Cargando…

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy

The utility of multigene expression assays in advanced (≥ 4 positive lymph nodes) early breast cancer (EBC) is limited. We conducted exploratory transcriptomic analysis of 758 genes (Breast Cancer 360 panel, nCounter(®) platform; NanoString) in primary tumor samples collected during a phase 3 trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinisch, Mattea, Bruzas, Simona, Gluz, Oleg, Ataseven, Beyhan, Schmid, Peter, Cortés, Javier, Blohmer, Jens‐Uwe, Shenoy, Satyendra, Dyson, Mark H., Dittmer‐Grabowski, Christine, Chiari, Ouafaa, Harrach, Hakima, Gebauer, Daniel, Traut, Alexander, Kuemmel, Sherko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257423/ https://www.ncbi.nlm.nih.gov/pubmed/37057719 http://dx.doi.org/10.1002/1878-0261.13435

Ejemplares similares

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
por: Bruzas, Simona, et al.
Publicado: (2022)

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
por: Reinisch, Mattea, et al.
Publicado: (2023)

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
por: Bruzas, Simona, et al.
Publicado: (2021)

Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers
por: Reinisch, Mattea, et al.
Publicado: (2021)

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
por: Kuemmel, Sherko, et al.
Publicado: (2020)

RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
por: Heil, Joerg, et al.
Publicado: (2018)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Dose-dense Temozolomide: Is It Still Promising?
por: NAGANE, Motoo
Publicado: (2015)

Dose-dense adjuvant chemotherapy for primary breast cancer
por: Fornier, Monica, et al.
Publicado: (2005)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma
por: Zhu, Chenjing, et al.
Publicado: (2017)

A case of squamous cell carcinoma of the breast achieved a pathological complete response after dose-dense AC + dose-dense PTX
por: Araki, Misato, et al.
Publicado: (2023)

Dose-dense chemotherapy for breast cancer: the story so far
por: Hudis, C
Publicado: (2000)

Efficacy and Safety of Auricular Acupuncture for the Treatment of Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial
por: Höxtermann, Melanie D., et al.
Publicado: (2021)

The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women’s response to integrative breast cancer treatment
por: Haller, Heidemarie, et al.
Publicado: (2021)

Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial
por: Haller, Heidemarie, et al.
Publicado: (2019)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer
por: Grote, Isabel, et al.
Publicado: (2022)

Autologous vs. implant-based breast reconstruction after skin- and nipple-sparing mastectomy—A deeper insight considering surgical and patient-reported outcomes
por: von Glinski, Maxi, et al.
Publicado: (2022)

The Partner Perspective on Autologous and Implant-Based Breast Reconstruction
por: von Glinski, Maxi, et al.
Publicado: (2023)

Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma
por: Maur, Michela, et al.
Publicado: (2015)

Pneumocystis jirovecii in a patient on dose‐dense chemotherapy for early breast cancer
por: Khoo, Chloe, et al.
Publicado: (2019)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
por: Ataseven, Beyhan, et al.
Publicado: (2020)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2014)

Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery”
por: Heitz, Florian, et al.
Publicado: (2016)

The effect of high dose digoxin on cytokines in healthy dogs.
por: Dülger, Haluk, et al.
Publicado: (2002)

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
por: Imterat, Majdi, et al.
Publicado: (2023)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

Pneumocystis jirovecii Pneumonia in a Patient with Breast Cancer Receiving Neoadjuvant Dose-dense Chemotherapy
por: Watanabe, Hirofumi, et al.
Publicado: (2019)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

Pneumocystis jirovecii Pneumonia in Three Patients With Breast Cancer Receiving Neoadjuvant Dose-Dense Chemotherapy
por: Shiiba, Ritsuya, et al.
Publicado: (2022)

Impact of Helium Ion Implantation Dose and Annealing on Dense Near-Surface Layers of NV Centers
por: Berzins, Andris, et al.
Publicado: (2022)

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
por: PETTY, W. JEFFREY, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g6scq718mrudmu6vu6hf6iejfl